N

Navamedic ASA
OSE:NAVA

Watchlist Manager
Navamedic ASA
OSE:NAVA
Watchlist
Price: 24.3 NOK -1.22%
Market Cap: 429.2m NOK
Have any thoughts about
Navamedic ASA?
Write Note
Section:
 

Relative Value

The Relative Value of one NAVA stock under the Base Case scenario is 71.44 NOK. Compared to the current market price of 24.3 NOK, Navamedic ASA is Undervalued by 66%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NAVA Relative Value
Base Case
71.44 NOK
Undervaluation 66%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

0.8
P/S
P/S
Price to Sales
0.8
vs History
96
vs Industry
67
Median 3Y
1.4
Median 5Y
1.4
Industry
2.5
Forward
0.8
More Details
17.4
P/E
P/E
Price to Earnings
17.4
vs History
50
vs Industry
1
Median 3Y
27.4
Median 5Y
18.1
Industry
21.4
Forward
14.9
More Details
76.5
P/OCF
P/OCF
Price to OCF
76.5
vs History
34
vs Industry
1
Median 3Y
61.3
Median 5Y
19.1
Industry
16
More Details
94.5
P/FCFE
P/FCFE
Price to FCFE
94.5
vs History
11
vs Industry
32
Median 3Y
14.2
Median 5Y
7.7
Industry
23.3
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
92
vs Industry
31
Median 3Y
2.9
Median 5Y
2.6
Industry
2.1
More Details
0.9
EV/S
EV/S
Enterprise Value to Sales
0.9
vs History
80
vs Industry
66
Median 3Y
1.5
Median 5Y
1.4
Industry
2.6
Forward
0.9
More Details
2.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.2
vs History
93
vs Industry
58
Median 3Y
3.5
Median 5Y
3.7
Industry
5.1
More Details
7.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.8
vs History
63
vs Industry
30
Median 3Y
14.1
Median 5Y
13.1
Industry
13.7
Forward
9.8
More Details
10.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.3
vs History
57
vs Industry
27
Median 3Y
17.9
Median 5Y
13.4
Industry
16.7
Forward
10.6
More Details
87.1
EV/OCF
EV/OCF
Enterprise Value to OCF
87.1
vs History
28
vs Industry
1
Median 3Y
61.5
Median 5Y
21.2
Industry
15.1
More Details
155.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
155.8
vs History
14
vs Industry
25
Median 3Y
22.8
Median 5Y
15.7
Industry
18.9
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
85
vs Industry
45
Median 3Y
2
Median 5Y
1.8
Industry
1.9
More Details

Multiples Across Competitors

NAVA Competitors Multiples
Navamedic ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Navamedic ASA
OSE:NAVA
428.8m NOK 0.8 17.4 7.8 10.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
753.7B USD 18.4 89.8 48.4 54
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 10.3 29.5 20.5 23.4
US
Johnson & Johnson
NYSE:JNJ
342B USD 3.9 23.3 11.3 14.7
US
Merck & Co Inc
NYSE:MRK
252.1B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
214.3B CHF 3.7 18.6 10.5 12.4
UK
AstraZeneca PLC
LSE:AZN
170.1B GBP 4.3 32.5 169.8 254.5
CH
Novartis AG
SIX:NOVN
178.4B CHF 3.9 11.1 9.6 13.4
US
Pfizer Inc
NYSE:PFE
152.2B USD 2.5 35.7 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average P/S: 382 942.1
0.8
12%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
7%
601 676.1
US
Eli Lilly and Co
NYSE:LLY
18.4
28%
0.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
21%
0.5
US
Johnson & Johnson
NYSE:JNJ
3.9
4%
1
US
Merck & Co Inc
NYSE:MRK
4
6%
0.7
CH
Roche Holding AG
SIX:ROG
3.7
5%
0.7
UK
AstraZeneca PLC
LSE:AZN
4.3
10%
0.4
CH
Novartis AG
SIX:NOVN
3.9
6%
0.7
US
Pfizer Inc
NYSE:PFE
2.5
3%
0.8
P/E Multiple
Earnings Growth PEG
NO
N
Navamedic ASA
OSE:NAVA
Average P/E: 31
17.4
177%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.8
76%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29.5
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.3
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
18.6
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32.5
40%
0.8
CH
Novartis AG
SIX:NOVN
11.1
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.7
102%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBITDA: 414.5
7.8
26%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.4
42%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.5
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.3
4%
2.8
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.5
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.8
18%
9.4
CH
Novartis AG
SIX:NOVN
9.6
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
N
Navamedic ASA
OSE:NAVA
Average EV/EBIT: 1 811.4
10.3
31%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
23.4
22%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
12.4
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
254.5
32%
8
CH
Novartis AG
SIX:NOVN
13.4
17%
0.8
US
Pfizer Inc
NYSE:PFE
16
19%
0.8

See Also

Summary
NAVA intrinsic value, competitors valuation, and company profile.
DCF Valuation
NAVA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NAVA stock valuation using valuation multiples.
Wall Street Estimates
NAVA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NAVA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 216,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.